In Brief: Elcelyx splits business, Hi-Tech quarterly results, e-cigarettes study, FDA warning letters
This article was originally published in The Tan Sheet
Executive Summary
Elcelyx spins out weight-loss supplement; Hi-Tech OTCs get boost from Mag-Ox; e-cigarettes effectively help smokers quit; Irenda “use by” dates require support, FDA says; FDA warns Metagenics over medical food claims; McNeil recalls Motrin product; FDA approves Perrigo’s bubble gum version of Zyrtec.
You may also be interested in...
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Elcelyx Continues Work On Weight Loss Supplement With $7 Mil. Financing
The Series B funding enables the San Diego biotech to advance a weight loss supplement to the cusp of commercialization. Elcelyx, also moving a delayed-release formulation of diabetes drug metformin into mid-stage trials, so far has received some $20 million in venture capital.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.